Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Phase 1CompletedNCT00502060

AstraZeneca65 enrolled

Overview

Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Tumor

Interventions

AZD2171DRUG

ZD1839DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * tumor progressed on standard therapy or ineligible for standard therapy * life expectancy of 12 weeks or more * WHO performance status 0-2 Exclusion Criteria: * History of active interstitial lung disease

Locations (3)

Research Site

Amsterdam, Netherlands

Research Site

Nijmegen, Netherlands

Research Site

Utrecht, Netherlands

Outcomes

Primary Outcomes

primary objective is to determine the safety and tolerability of multiple oral doses fo AZD2171 when co-administered with fixed daily oral doses of ZD1839

Secondary Outcomes

to explore the PK of AZD2171 when given alone for 7 days and in combination with ZD1839 for 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.